Does neoadjuvant therapy alter KRAS and/or MSI results in rectal adenocarcinoma testing?

American Journal of Surgical Pathology

Volumn 35, Issue 9, 2011, Pages 1327-1330

  Ondrejka, Sarah L ^a   Schaeffer, David F ^b   Jakubowski, Maureen A ^a   Owen, David A ^b   Bronner, Mary P ^a,c  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

molecular test results; neoadjuvant chemoradiotherapy; rectal adenocarcinoma

Indexed keywords

KRAS PROTEIN, HUMAN; ONCOPROTEIN; RAS PROTEIN;

ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ARTICLE; BIOPSY; CANADA; CLINICAL TRIAL; CODON; GENETIC SCREENING; GENETICS; HUMAN; METHODOLOGY; MICROSATELLITE INSTABILITY; MULTICENTER STUDY; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; RECTUM TUMOR; TREATMENT OUTCOME; UNITED STATES;

ADENOCARCINOMA; BIOPSY; BRITISH COLUMBIA; CHEMOTHERAPY, ADJUVANT; CODON; DNA MUTATIONAL ANALYSIS; GENETIC TESTING; HUMANS; MICROSATELLITE INSTABILITY; MUTATION; NEOADJUVANT THERAPY; OHIO; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE OF TESTS; PROTO-ONCOGENE PROTEINS; RADIOTHERAPY, ADJUVANT; RAS PROTEINS; RECTAL NEOPLASMS; TREATMENT OUTCOME;

EID: 81155159839     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e3182253800     Document Type: Article

References (16)

1. Allegra CJ, Jessup JM, Somerfield MR, et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol. 2009;27:2091-2096.
2. Bao F, Panarelli NC, Rennert H, et al. Neoadjuvant therapy induces loss of MSH6 expression in colorectal adenocarcinoma. Am J Surg Pathol. 2010;34:1798-1804.
3. Bertagnolli MM, Neidzwiecki D, Compton CC, et al. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. J Clin Oncol. 2009;27:1814-1821.
4. Bertolini F, Bengala C, Losi L, et al. Prognostic and predictive value of baseline and posttreatment molecular marker expression in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2007;68:1455-1461. (Pubitemid 47176800)
5. Boland CR, Thibodeau SN, Hamilton SR, et al. A national cancer institute workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 1998;58:5248-5257. (Pubitemid 28521189)
6. Buonanno M, de Toledo SM, Pain D, et al. Long-term consequences of radiation-induced bystander effects depend on radiation quality and dose and correlate with oxidative stress. Radiat Res. 2011. [Epub ahead of print].
7. Charara M, Edmonston TB, Burkholder S, et al. Microsatellite status and cell cycle associated markers in rectal cancer patients undergoing a combined regimen of 5-FU and CPT-11 chemotherapy and radiotherapy. Anticancer Res. 2004;24:3161-3167. (Pubitemid 39390968)
8. Choi MY, Lauwers GY, Hur C, et al. Microsatellite instability is frequently observed in rectal cancer and influenced by neoadjuvant chemoradiation. Int J Radiat Oncol Boil Phys. 2007;68:1584. (Pubitemid 47176835)
9. Colombino M, Cossu A, Manca A, et al. Prevalence and prognostic role of microsatellite instability in patients with rectal carcinoma. Ann Oncol. 2002;13:1447-1453.
10. Hurley LH. DNA and its associated processes as targets for cancer therapy. Nat Rev Cancer. 2002;2:188-200. (Pubitemid 37328788)
11. Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol. 2005;23:609-618. (Pubitemid 46224239)
12. Ribic CM, Sargent DJ, MooreMJ, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med. 2003;349:247-257. (Pubitemid 36859476)
13. Salovaara R, Loukola A, Kristo P, et al. Population-based molecular detection of hereditary nonpolyposis colorectal cancer. J Clin Oncol. 2000;18:2193-2200. (Pubitemid 30350210)
14. Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351:1731-1739.
15. Umar A, Boland CR, Terdiman JP, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst. 2004;96:261-268. (Pubitemid 38256271)
16. Watson P, Lynch HT. Extracolonic cancer in hereditary nonpolyposis colorectal cancer. Cancer. 1993;71:677-685. (Pubitemid 23051366)